Maravai Lifesciences Holdings (MRVI) Total Liabilities (2020 - 2026)
Maravai Lifesciences Holdings (MRVI) posted quarterly Total Liabilities of $344.1 million for Q1 2026, down 19.87% year-over-year from $429.5 million in Q1 2025, and down 13.51% quarter-over-quarter from $397.9 million in Q4 2025.
Maravai Lifesciences Holdings (MRVI) Total Liabilities (2020 - 2026) Analysis & Trends
Maravai Lifesciences Holdings' Total Liabilities history runs 7 years deep, the most recent figure standing at $344.1 million for Q1 2026.
- In Q1 2026, Total Liabilities fell 19.87% year-over-year to $344.1 million; the TTM figure through Mar 2026 stood at $344.1 million (down 19.87% YoY), while the FY2025 annual figure was $397.9 million, down 7.7% from the prior year.
- Total Liabilities for Q1 2026 stood at $344.1 million, down from $397.9 million in the prior quarter.
- The five-year high for Total Liabilities was $1.4 billion in Q1 2023, with the low at $344.1 million in Q1 2026.
- The 5-year median for Total Liabilities is $671.3 million (2024), against an average of $875.2 million.
- The sharpest annual moves came in 2022 and 2024: Total Liabilities increased 21.62% in 2022, then slumped 52.84% in 2024.
- Maravai Lifesciences Holdings' Total Liabilities stood at $1.4 billion in 2022, then plunged by 49.34% to $697.6 million in 2023, then plunged by 38.21% to $431.0 million in 2024, then fell by 7.7% to $397.9 million in 2025, then retreated by 13.51% to $344.1 million in 2026.
- Business Quant data shows MRVI's Total Liabilities at $344.1 million in Q1 2026, $397.9 million in Q4 2025, and $417.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.62 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.72 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 4.00 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 7.02 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 10.03 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.35 Bn |
| 10 | Maravai Lifesciences Holdings | 1.48 Bn | 1.56 Bn | 20.65 Mn | 248.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 248.16 Mn |
| Mar 31, 2026 | 344.13 Mn |
| Dec 31, 2025 | 397.87 Mn |
| Sep 30, 2025 | 417.33 Mn |
| Jun 30, 2025 | 428.98 Mn |
| Mar 31, 2025 | 429.48 Mn |
| Dec 31, 2024 | 431.04 Mn |
| Sep 30, 2024 | 665.56 Mn |
| Jun 30, 2024 | 671.26 Mn |
| Mar 31, 2024 | 667.25 Mn |
| Dec 31, 2023 | 697.57 Mn |
| Sep 30, 2023 | 1.38 Bn |
| Jun 30, 2023 | 1.37 Bn |
| Mar 31, 2023 | 1.41 Bn |
| Dec 31, 2022 | 1.38 Bn |
| Sep 30, 2022 | 1.41 Bn |
| Jun 30, 2022 | 1.40 Bn |
| Mar 31, 2022 | 1.39 Bn |
| Dec 31, 2021 | 1.37 Bn |
| Sep 30, 2021 | 1.44 Bn |